

# Cell Proliferation and Apoptotic Indices Predict Adenoma Regression in a Placebo-Controlled Trial of Celecoxib in Familial Adenomatous Polyposis Patients

Frank A. Sinicrope,<sup>1</sup> Elizabeth Half,<sup>1</sup> Jeffrey S. Morris,<sup>2</sup> Patrick M. Lynch,<sup>1</sup> Jason D. Morrow,<sup>5</sup> Bernard Levin,<sup>1</sup> Ernest T. Hawk,<sup>4</sup> Deborah S. Cohen,<sup>2</sup> Gregory D. Ayers,<sup>2</sup> L. Clifton Stephens,<sup>3</sup> and Familial Adenomatous Polyposis Study Group

Departments of <sup>1</sup>Gastrointestinal Medicine and Nutrition, <sup>2</sup>Biostatistics, and <sup>3</sup>Veterinary Medicine and Surgery, University of Texas M.D. Anderson Cancer Center, Houston, Texas; <sup>4</sup>National Cancer Institute, Bethesda, MD; and <sup>5</sup>Department of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee

## Abstract

**Background:** Celecoxib was shown to regress colorectal adenomas in familial adenomatous polyposis (FAP) patients relative to placebo. To address the mechanism of polyp regression, we determined whether celecoxib can modulate cell proliferation, apoptosis, and prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) levels in colorectal epithelia from FAP trial participants and whether such alterations correlate with observed reductions in polyp number. **Materials and Methods:** Colorectal mucosal biopsies were obtained at baseline and on last day of celecoxib (100 or 400 mg twice daily) or placebo administration (6 months). Residual paraffin-embedded adenomas and normal mucosa from the same patients (*n* = 17) or normal tissue alone (*n* = 15) were analyzed. Immunoperoxidase staining for Ki-67 was performed and apoptotic cells were identified by their morphology. Ki-67 and apoptotic labeling indices and their ratios were calculated in superficial (s) and nonsuperficial (ns) regions of adenomas and normal mucosa, and baseline to 6-month differences were calculated. PGE<sub>2</sub> levels were analyzed by mass spectroscopy (normal, *n* = 64; adenoma, *n* = 56). Biomarkers were analyzed by treatment arm and correlated with previously determined mean percentage reductions in colorectal polyp

number. **Results:** In adenomas, a reduction in the superficial proliferative activity i.e., Ki-67<sub>s</sub> labeling index, accompanied polyp regression (*r* = -0.76, *P* = 0.006). An increase in the apoptotic ratio [i.e., superficial apoptotic index (AI<sub>s</sub>)/nonsuperficial apoptotic index (AI<sub>ns</sub>)] was found to correlate with reduced polyp counts in that higher apoptotic ratios correlated with better response to celecoxib (*r* = 0.71, *P* = 0.004). Furthermore, the AI<sub>s</sub>/Ki-67<sub>s</sub> ratio (*r* = 0.58, *P* = 0.026) accompanied polyp regression. In normal mucosa, a trend toward increased AI<sub>s</sub> (*r* = 0.33, *P* = 0.053) and polyp regression was found. PGE<sub>2</sub> levels did not significantly correlate with polyp regression. Changes in biomarker levels (baseline to 6 months) were correlated in adenomas and normal mucosa (AI<sub>s</sub>, *r* = 0.29, *P* = 0.024; AI<sub>ns</sub>, *r* = 0.34, *P* = 0.009; PGE<sub>2</sub>, *r* = 0.50, *P* = 0.059) within individual patients. **Conclusion:** Suppression of cell proliferation and an increased apoptotic ratio, as well as the ratio of apoptosis to cell proliferation, accompany polyp regression in a chemoprevention trial in FAP patients. These findings suggest potential mechanisms for the efficacy of celecoxib and warrant further study of these biomarkers as intermediate endpoints in FAP patients. (Cancer Epidemiol Biomarkers Prev 2004;13(6):920-7)

## Introduction

Epidemiologic studies have consistently shown an inverse association between long-term intake of nonsteroidal anti-inflammatory drugs (NSAIDs), especially aspirin, and incidence of colorectal adenomas and carcinomas relative to nonusers (reviewed in ref. 1). NSAIDs, including selective cyclooxygenase (COX)-2 inhibitors, are potent inhibitors of intestinal tumor

incidence and multiplicity in carcinogen-induced and genetically manipulated animal models of colon cancer (reviewed in ref. 2). In patients with familial adenomatous polyposis (FAP), the NSAID sulindac has been shown to regress rectal polyps in uncontrolled studies (3-5) as well as in placebo-controlled trials (6, 7). FAP is an autosomal dominant disorder that is due to a germline mutation in the adenomatous polyposis (*APC*) gene on human chromosome 5 (8). The FAP phenotype consists of at least hundreds of colorectal adenomas and the eventual development of colorectal cancer (3-7). Recently, the selective COX-2 inhibitor celecoxib given continuously to FAP patients for 6 months was found to significantly regress the number of colorectal adenomas compared with placebo (9). Specifically, high-dose (400 mg twice daily) but not lower-dose (100 mg twice daily) celecoxib produced significant polyp regression in comparison with placebo. In an effort to gain insights into the mechanism of celecoxib-induced polyp

Received 6/13/03; revised 2/11/04; accepted 2/23/04.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Note:** FAP Study Group: R.K.S. Phillips, M.H. Wallace, and B.P. Saunders (St. Mark's Hospital and Imperial Cancer Research Fund, Harrow, United Kingdom); G. Steinbach, W. Hittelman, and S. Patterson (University of Texas M.D. Anderson Cancer Center, Houston, Texas); R.N. DuBois (Vanderbilt University Medical Center, Nashville, Tennessee); and G.B. Gordon (GD Searle & Co., Skokie, Illinois).

**Requests for reprints:** Frank A. Sinicrope, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Phone: 507-266-0132; Fax: 507-266-0350. E-mail: sinicrope.frank@mayo.edu

regression, we evaluated mucosal biomarkers in tissue specimens pretreatment and posttreatment from this clinical trial and determined their correlation with polyp response data.

COX enzymes regulate prostaglandin (PG) synthesis from arachidonic acid and are the best defined molecular targets of NSAIDs (2). Two COX isoforms have been identified and include constitutive COX-1 and inducible COX-2. COX-2 is induced by cytokines, growth factors, and tumor promoters (10) and its expression is up-regulated at sites of inflammation and in certain neoplastic epithelia, including colorectal adenomas and carcinomas (11-13). The best evidence for the role of COX-2 in intestinal tumorigenesis derives from mice with a mutation in the *APC* gene (*APC*<sup>716</sup>), which, when mated to COX-2 knockout mice, resulted in double-knockout progeny with a dramatic reduction in intestinal polyp burden (14). While the exact mechanism(s) by which COX-2 contributes to intestinal tumorigenesis remains unknown, studies indicate that COX-2 may inhibit apoptosis, promote angiogenesis, and increase tumor cell invasiveness (2). Selective COX-2 inhibitors (i.e., coxibs) were developed which exert an anti-inflammatory effect but are associated with significantly less gastrointestinal mucosal injury compared with nonselective NSAIDs (15, 16). In animal models of colon cancer, the coxibs appear at least as efficacious as traditional NSAIDs in suppressing intestinal tumor development (3). While PG inhibition is the best studied antitumor mechanism of NSAIDs, COX-independent mechanisms also exist and experimental studies have consistently shown their importance (2).

Epithelial homeostasis is maintained by a balance between cell proliferation and apoptosis (17). A disruption in cellular kinetics in intestinal epithelia may cause tumors (18). In normal colorectal mucosa, proliferating cells are in the lower one-third of crypts, and apoptotic cells are detected near or at the luminal surface (17). In normal-appearing colonic epithelium from FAP patients, a significant shift in the proliferative compartment toward the luminal surface is seen, as is a reduction in apoptosis at the cell surface (19, 20). These changes appear to accompany adenoma development. Furthermore, Bedi et al. (20) reported a progressive decrease in apoptotic rates during colorectal tumorigenesis in FAP. We (21) and Moss et al. (22) reported that adenomas demonstrate an inverted apoptotic gradient relative to normal colorectal mucosa. Taken together, these findings suggest that suppression of apoptosis and expansion of the proliferative compartment are key events during colorectal neoplastic development and progression.

We sought to test the hypothesis that celecoxib induces polyp regression in FAP by modulating *in vivo* rates of cell proliferation and apoptosis. In support of this hypothesis are abundant data demonstrating that NSAIDs and coxibs inhibit cell proliferation and induce apoptosis in cultured colon cancer cell lines (23-26). However, the doses of NSAIDs found to exert these effects *in vitro* have generally been in excess of doses that can be achieved *in vivo*, thereby casting suspicion as to the clinical relevance of these findings. Yet, in intestinal tissues from animal models of colon cancer treated with NSAIDs, modulation of rates of apoptosis and cell proliferation were found and were associated with tumor inhibition and/or regression (27-29).

We analyzed and compared mucosal biomarkers including apoptotic and proliferative indices and PGE<sub>2</sub> levels in biopsies of normal-appearing colorectal mucosa and adenomas obtained at baseline and at 6 months in FAP patients treated in a randomized, placebo-controlled trial of celecoxib (high and low dose) versus placebo (9). Correlations were sought between biomarker levels and treatment arm as well as the primary study endpoint (i.e., percentage change in colorectal polyp number at 6 months relative to baseline).

## Materials and Methods

**Patient Population and Tissue Resource.** FAP patients were enrolled in a randomized, double-blinded, placebo-controlled trial to determine the effect of two doses of celecoxib on colorectal polyps as reported previously (9). Eligible patients had a genotype and phenotype consistent with FAP, were 18 to 65 years of age, and had five or more polyps 2 mm or greater in diameter that could be assessed endoscopically. Patients with intact colons or ileorectal anastomoses were eligible. Patients (*n* = 77) received either of two celecoxib doses (100 or 400 mg twice daily) or placebo given continuously for 6 months. The primary study endpoint was the percentage reduction in the number of colorectal polyps at 6 months compared with the baseline colonoscopic examinations. Informed consent was obtained from all patients, and the protocol was approved by the Institutional Review Board of the University of Texas M.D. Anderson Cancer Center. Pretreatment and posttreatment biopsies were obtained at baseline and on the last day of drug administration. A rigorous biopsy protocol was used to obtain tissue specimens for biomarker studies, thus ensuring standardized collection. For collection of normal-appearing mucosa, the endoscopist biopsied areas where no polypoid tissue or mucosal elevations were identified at endoscopy. Specimens of normal-appearing mucosa (*n* = 64) and adenomatous polyps (*n* = 56) were snap-frozen for PGE<sub>2</sub> analysis. Residual, paired paraffin-embedded sections of normal colorectal mucosa (*n* = 15) and adenomas (*n* = 17) were available for analysis. These specimens had been fixed in 10% neutral-buffered formalin and embedded in paraffin, and four to six micron sections were subsequently cut for immunohistochemistry. A section from each tissue specimen was stained with H&E for analysis of histology.

**Cell Proliferation and Apoptosis.** Endoscopic biopsy specimens were examined for cell proliferation by measuring Ki-67 protein expression. Immunoperoxidase staining was performed using an anti-Ki-67 polyclonal antibody (DAKO Corp., Carpinteria, CA), as described below. Apoptotic cells and bodies were identified in H&E-stained tissue sections using established morphologic criteria that were uniformly applied to all specimens examined (17, 18, 21, 30). The analysis of apoptotic and proliferative indices was restricted to epithelial cells. Calculation of labeling indices (LIs) is described below.

**Immunohistochemistry for Ki-67.** Slides were deparaffinized and endogenous peroxidase activity was blocked by incubation in 3% H<sub>2</sub>O<sub>2</sub> in methanol for 20 minutes at room temperature. Sections were microwaved in PBS

(pH 7.4) for 4 minutes for antigen retrieval. An immunoperoxidase method was used (Vectastain Elite avidin-biotin complex method, Vector Laboratories, Burlingame, CA). Nonspecific binding was blocked with avidin and biotin (Vector Laboratories) for 15 minutes each. An anti-Ki-67 polyclonal antibody (M1B1, 1:125 dilution, DAKO) was used and applied for 1 hour at room temperature (31). After slides were rinsed in PBS, the biotinylated secondary immunoglobulin antibody (LSAB2 system, DAKO) was applied for 15 minutes at room temperature. Slides were rinsed in PBS, and avidin conjugated to horseradish peroxidase (LSAB2 system, DAKO) was applied for 15 minutes at room temperature. The chromogen 3,3'-diaminobenzidine was subsequently added, and the color reaction was observed at light microscopy. The reaction was stopped by immersing slides in deionized water. Slides were counterstained with hematoxylin and mounted. A human colorectal cancer known to intensely stain for Ki-67 was included with all slide runs (positive control). A negative control was included with each slide run and omitted the primary antibody but included all other procedural steps.

**Labeling Indices.** LIs were determined in adenomas and normal mucosal biopsy specimens at light microscopy. Apoptotic or proliferative (Ki-67 staining) LIs were determined independently and calculated by counting the number of apoptotic or Ki-67-positive nuclei per 500 cells examined in five high-power fields (400 $\times$ ) per slide, with the result expressed as a percentage (21, 31). LIs were determined in both superficial and nonsuperficial regions of adenomas and normal mucosa. Superficial regions included intact and nondetached normal or neoplastic cells in the top two epithelial cell layers including cells at or near the luminal surface. Nonsuperficial regions included all other regions, except for basal colonic crypts identified by the presence of the mucularis mucosae in normal tissue sections. Apoptotic cells and bodies detected in colon carcinoma sections by morphology have been shown to contain DNA strand breaks using terminal deoxynucleotidyl transferase-mediated nick end labeling assay (21). Quantification of LIs was performed by a single observer who has considerable experience in quantifying apoptosis in histologic sections and who was blinded to all clinical data. Furthermore, biomarker ratios of superficial proliferative activity (Ki-67<sub>s</sub>)/nonsuperficial proliferative activity (Ki-67<sub>ns</sub>), superficial apoptotic index (AI<sub>s</sub>)/nonsuperficial apoptotic index (AI<sub>ns</sub>), and AI<sub>s</sub>/Ki-67<sub>s</sub> and AI<sub>ns</sub>/Ki-67<sub>ns</sub> were also computed. Biomarker levels were determined at both baseline and 6-month time points, and the absolute change between these time points was calculated.

**PGE<sub>2</sub> Content in Mucosal Biopsies.** PGE<sub>2</sub> levels were quantified in two snap-frozen biopsy specimens at baseline and 6-month examinations and were stored at -70°C as determined previously (32). To extract PGE<sub>2</sub>, frozen samples were submerged in a pestle containing liquid nitrogen and pulverized with a mortar. After the nitrogen evaporated, the sample was immediately mixed with 0.5 ml methanol containing 10  $\mu$ mol/L indomethacin that had been cooled to -20°C. The mixture was allowed to warm to 4°C and was diluted with water (pH 3). [<sup>3</sup>H<sub>4</sub>]-PGE<sub>2</sub> (1.5 ng) was added to the aqueous tissue homogenate as an internal standard and the solu-

tion was adjusted to pH 3. The sample was applied to a C-18 Sep-Pak cartridge that had been prewashed with 5 mL methanol and 5 mL H<sub>2</sub>O (pH 3). The cartridge was washed with 10 mL H<sub>2</sub>O (pH 3) followed by 10 mL heptane, and compounds were eluted with 10 mL ethyl acetate. The eluate was applied to a silica Sep-Pak cartridge and rinsed with 5 mL ethyl acetate, and compounds were eluted with 5 mL ethyl acetate/methanol (50:50 v/v) and dried under nitrogen. Compounds were methoximated by treatment with 2% solution of aqueous methoxyamine-HCl (250  $\mu$ L) for 30 min at room temperature and extracted with 1 mL ethyl acetate. The organic layer evaporated under nitrogen. Conversion to a pentafluorobenzyl ester was performed by the addition of 40  $\mu$ L pentafluorobenzyl bromide (10% solution) in acetonitrile and 20  $\mu$ L diisopropylethanolamine in acetonitrile (10% solution) and allowed to incubate for 30 minutes at 37°C. Reagents were dried under nitrogen, and the residue was reconstituted in 30  $\mu$ L chloroform and 20  $\mu$ L methanol and chromatographed on a silica TLC plate to 13 cm in a solvent system of ethyl acetate/methanol (98:2 v/v). The methyl ester of PGE<sub>2</sub> and the *O*-methyloxime, pentafluorobenzyl ester derivative PGD<sub>2</sub> (~5  $\mu$ g each) were chromatographed on a separate lane and visualized with 10% phosphomolybdic acid in ethanol by heating. Compounds migrating in the region 1 cm above the PGF<sub>20</sub> standard to 1.5 cm below the PGD<sub>2</sub> standard are scraped from the TLC plate, extracted with 1 ml ethyl acetate, and dried under nitrogen. Following TLC purification, compounds are converted to trimethylsilyl ether derivatives by addition of 20  $\mu$ L *N,O*-bis(trimethylsilyl)trifluoroacetamide and 10  $\mu$ L dimethylformamide. The sample is incubated at 37°C for 10 minutes and dried under nitrogen. The residue is redissolved for gas chromatographic/mass spectrometric analysis in 10  $\mu$ L undecane.

**Mass Spectroscopy.** Gas chromatography/negative ion chemical ionization/mass spectrometry was carried out on a Hewlett-Packard 5982A mass spectrometer (Palo Alto, CA), calibrated daily, and interfaced with an IBM Pentium computer. Gas chromatography is performed using a 15 m, 0.25  $\mu$ m film thickness DB-1701 fused silica capillary column (J&W Scientific, Folsom, CA). The column temperature is programmed from 190°C to 300°C at 20°C/min. The major ion generated in the negative ion chemical ionization mass spectrum of the pentafluorobenzyl ester, *O*-methyloxime, tetramethylsilane or tetramethylsilyl ether derivative of PGE<sub>2</sub> is the *m/z* 524 carboxylate anion [M-181 (N-CH<sub>2</sub>C<sub>8</sub>F<sub>5</sub>)]. The corresponding ion generated by the [<sup>2</sup>H<sub>4</sub>]-PGE<sub>2</sub> internal standard is *m/x* 528. Endogenous PGE<sub>2</sub> levels are calculated from the ratio of intensities of the ions *m/z* 524 to *m/z* 528. As part of the assay procedure, a blank and a control sample containing a known amount of eicosanoid were assayed with each batch as quality control measures.

**Statistical Considerations.** The major statistical endpoint in this study was the correlation between mucosal biomarkers and response to treatment (i.e., percentage reduction in number of colorectal polyps at 6 months from baseline). Additionally, biomarker levels were analyzed in relation to study treatment arm. The biomarkers assessed included apoptotic and proliferative LIs and

PGE<sub>2</sub> levels. Biomarkers of interest included the apoptotic or proliferative (Ki-67) LIs in the superficial and nonsuperficial compartments and their respective ratios. The relationship between biomarker levels and clinical response were assessed using Spearman correlations between the absolute change in biomarker levels from baseline to 6 months and the percentage reduction in polyp number from baseline to 6 months. The primary analysis was done using Spearman correlation coefficients, which are based on the ranks of the data. Because they are computed on the ranks, they are robust to outliers and do not require linearity in the scale of the data. Scatter plots were also generated to show the actual data on which the Spearman correlations were computed. The relationship between biomarker levels and study arm was assessed using nonparametric rank sum tests. The primary focus was placed on the placebo versus 400 mg twice daily celecoxib comparison, because this was the comparison that demonstrated the chemopreventive efficacy of celecoxib. Additionally, we examined the correlation between biomarker values within individual patients using Spearman correlations. All statistical tests were conducted with a significance level of 0.05.

## Results

The results of this clinical trial in FAP patients have been published (9) and are summarized below. At baseline, the mean ( $\pm$  SD) number of polyps in focal areas where polyps were counted was  $15.5 \pm 13.4$  in the 15 patients assigned to placebo,  $11.5 \pm 8.5$  in the 32 patients assigned to 100 mg of celecoxib twice daily, and  $12.3 \pm 8.2$  in the 30 patients assigned to 400 mg of celecoxib twice daily ( $P = 0.66$ ) for the comparison among groups. After 6 months of continuous drug treatment, the patients receiving 400 mg celecoxib twice daily had a 28.0% reduction in the mean number of colorectal polyps ( $P = 0.003$  for the comparison with placebo) as compared with a reduction of 4.5% in the placebo group. The reduction in the group receiving 100 mg celecoxib twice

daily was 11.9% ( $P = 0.33$  for the comparison with placebo). The improvement in the extent of colorectal polyposis in the treatment groups was confirmed by a panel of endoscopists who reviewed procedure videotapes in a blinded manner. The incidence of adverse events was similar among the groups. More than 90% of patients completing the study took 80% of the study drug.


We retrospectively examined a panel of biomarkers in normal mucosa and in adenoma tissue from FAP clinical trial participants. Our aim was to determine whether modulation of the selected biomarkers correlated with the primary clinical study endpoint (i.e., the percentage change in colorectal polyp number at 6 months relative to baseline). To this aim, we determined the absolute change in a given biomarker from baseline to 6 months and sought its correlation with treatment arm and with polyp response data. We regarded this correlation as most important for providing mechanistic insights into the antitumor effects of celecoxib *in vivo*.

**Apoptotic and Proliferative Indices.** Apoptotic and proliferative indices were determined in superficial (AI<sub>s</sub> and Ki-67<sub>s</sub>) and nonsuperficial (AI<sub>ns</sub> and Ki-67<sub>ns</sub>) regions of normal-appearing colorectal mucosa and in adenoma specimens from baseline and 6-month (end of study) examinations (Table 1). The change in each biomarker (baseline to 6 months) was determined and ratios between AI<sub>s</sub> or AI<sub>ns</sub> and Ki-67<sub>s</sub> or Ki-67<sub>ns</sub> were computed. A significant reduction in Ki-67<sub>s</sub> in adenomas was seen at 6 months relative to baseline ( $P = 0.016$ ; Table 1). No significant differences were found for apoptotic indices in adenomas between these time points, nor were any significant differences found for these biomarkers in normal mucosa.

**Correlation between Apoptotic and Proliferative Indices and Polyp Regression.** We investigated whether biomarker values are related to clinical response, defined as the percentage change in polyp number from baseline to 6 months. In this study, the mean reduction in colorectal polyp number was  $-4.5\%$  for placebo,  $-11.9\%$  for

**Table 1. Summary of median values and ranges for apoptotic and proliferative indices and PGE<sub>2</sub> expression**

Biomarker	Histology	Study Evaluation (mo)	Mean	Median	Min	Max	<i>n</i>
AI <sub>s</sub>	Normal	Baseline	0.81	0.80	0.00	1.80	37
		6 months	0.78	0.60	0.00	3.00	34
	Polyp	Baseline	1.49	1.00	0.00	11.20	23
		6 months	1.38	1.40	0.00	2.60	19
AI <sub>ns</sub>	Normal	Baseline	0.48	0.40	0.00	1.60	37
		6 months	0.59	0.40	0.00	3.60	34
	Polyp	Baseline	0.99	0.80	0.20	4.00	23
		6 months	1.93	1.00	0.00	7.40	17
Ki-67 <sub>s</sub> LI	Normal	Baseline	4.16	0.40	0.00	75.00	36
		6 months	5.69	0.20	0.00	69.20	31
	Polyp	Baseline	51.87	55.60	11.00	85.00	23
		6 months	46.57	46.80	16.40	80.60	17
Ki-67 <sub>ns</sub> LI	Normal	Baseline	25.79	24.60	5.00	67.80	36
		6 months	29.40	30.20	5.00	66.40	31
	Polyp	Baseline	29.33	25.40	10.20	71.40	23
		6 months	28.06	26.80	10.80	58.40	19
PGE <sub>2</sub> (pg/ $\mu$ g protein)	Normal	Baseline	64.36	32.28	4.10	415.30	74
		6 months	91.88	51.08	6.83	614.00	65
	Polyp	Baseline	80.89	52.40	4.58	467.75	70
		6 months	112.01	75.43	3.11	454.45	57



**Figure 1.** Scatter plots of the change in biomarker levels (baseline to 6 months; x axis) versus percentage reduction in polyp number (y axis) for adenomas (A, B, and C) and normal-appearing colorectal mucosa (D). Treatment arms include 400 mg ( $\times$ ) and 100 mg (+) celecoxib twice daily or placebo (O). **A.** A reduction in the Ki-67<sub>s</sub> LI correlates with polyp regression in FAP patients. **B.** An increase in AI<sub>s</sub>/AI<sub>ns</sub> ratio of adenomas is positively correlated with polyp regression. **C.** An increase in AI<sub>s</sub>/Ki-67<sub>s</sub> ratio accompanies polyp regression. **D.** In normal mucosa, the AI<sub>s</sub> is associated with polyp regression.

low-dose celecoxib, and  $-28\%$  for high-dose celecoxib (9). We regarded the correlation between biomarker levels and clinical response to suggest modulation by celecoxib and to indicate a mechanism of polyp regression. For each biomarker and tissue type, we calculated the correlation between polyp response and (1) biomarker value at baseline and 6 months and (2) absolute change in biomarker from baseline to 6 months. Scatter plots of change in biomarker values versus polyp regression in adenoma and normal tissue versus polyp regression are shown in Fig. 1A-D and are discussed below.

**Adenomas.** We found that the change in the Ki-67<sub>s</sub> LI in adenomas from baseline to 6 months was significantly correlated with polyp regression ( $r = 0.72$ ,  $P = 0.0055$ ; Fig. 1A). Patients whose adenomas showed the greatest reduction in Ki-67<sub>s</sub> LIs over the study period had the best clinical response. The change in the apoptotic ratio of AI<sub>s</sub>/AI<sub>ns</sub> ( $r = 0.71$ ,  $P = 0.004$ ) was significantly correlated with polyp regression (Fig. 1B). This change represented an increase in apoptosis at or near the luminal surface

and a concomitant decrease in the nonsuperficial region. Furthermore, the change in the AI<sub>s</sub>/Ki-67<sub>s</sub> ratio also correlated with clinical response ( $r = 0.58$ ,  $P = 0.026$ ; Fig. 1C). These data suggest that the extent of superficial apoptosis and cell proliferation are modulated in association with celecoxib-induced polyp regression. No other significant relationships were found either for individual biomarkers or for their ratios in adenomas. We also analyzed the relationship between treatment arm and absolute change in the biomarker level from baseline to 6 months. Emphasis was placed on the comparison between high-dose celecoxib and placebo, given that significant polyp regression was seen for this comparison. An association between celecoxib dose and Ki-67<sub>s</sub> LI in adenomas was suggested when comparing the higher dose (400 mg twice daily) to the placebo group from baseline to 6 months ( $-1.34$  for placebo and  $-16.28$  for 400 mg), but this difference did not reach statistical significance ( $P = 0.077$ ) given the small sample size. Correlations between biomarker levels in normal colorectal mucosa and adenomas were sought. We found a positive

correlation between normal and adenoma tissue for measurements of  $AI_s$  ( $r = 0.29$ ,  $P = 0.02$ ) and  $AI_{ns}$  ( $r = 0.34$ ,  $P = 0.01$ ) within individual patients, suggesting that similar modulation is occurring in both normal and neoplastic tissues.

**Normal Mucosa.** In normal-appearing colorectal epithelia, the change in the  $AI_s$  (baseline to 6 months) correlated with polyp regression ( $r = 0.33$ ,  $P = 0.053$ ). In this regard, the largest increases in  $AI_s$  occurred in patients with greater percentage reductions in polyp number. No association was found between  $Ki-67_s$  LI and polyp regression over the treatment period ( $r = -0.04$ ,  $P = 0.86$ ), nor for any of the ratios examined.

**PGE<sub>2</sub> Levels.** PGE<sub>2</sub> levels were determined both in normal-appearing colorectal mucosa and in adenomas (Table 1). No significant differences were found in median PGE<sub>2</sub> levels comparing normal and adenoma tissue at baseline ( $P = 0.17$ ), 6 months ( $P = 0.45$ ), or the change in PGE<sub>2</sub> over this interval ( $P = 0.86$ ). Specifically, PGE<sub>2</sub> levels were not reduced in biopsy specimens at 6 months relative to baseline in either normal tissue or adenomas, indicating that celecoxib treatment failed to suppress PGE<sub>2</sub> production. PGE<sub>2</sub> levels did not differ significantly among treatment arms. Importantly, more than 90% of the patients who completed the study took at least 80% of the study drug, suggesting that non-compliance is unlikely to account for these negative results. Furthermore, the changes in PGE<sub>2</sub> levels from baseline to 6 months for normal epithelia ( $r = 0.02$ ,  $P = 0.84$ ) and adenomas ( $r = 0.05$ ,  $P = 0.71$ ) were not significantly associated with polyp regression. Within individual patients, PGE<sub>2</sub> levels were positively correlated between normal and polyp tissues ( $r = 0.50$ ,  $P = 0.06$ ).

## Discussion

Celecoxib was shown in a placebo-controlled trial study to significantly regress colorectal polyps in FAP patients administered this drug at a high dose (400 mg twice daily) for a continuous period of 6 months (9). Specimens from patients treated in this trial provided a unique tissue resource in which to analyze biomarkers that may be mechanistically related to the antitumor efficacy of celecoxib and may therefore be associated with the clinical response to this agent. In this study, we analyzed biomarkers, including cell proliferation and apoptosis, shown to be modulated experimentally by celecoxib and other NSAIDs (23-29) in adenomas and in normal-appearing mucosa. We also analyzed the biosynthetic product (i.e., PGE<sub>2</sub>) of the COX-2 enzyme in tissues from FAP study participants. We found that significant reductions in cell proliferation, as measured by the  $Ki-67$  LI, in the superficial compartment of adenomas accompanied their regression in FAP patients. Alteration in the ratio of apoptosis at or near the mucosa surface ( $AI_s$ ) compared with the nonsuperficial region ( $AI_{ns}$ ) was also found to significantly correlate with polyp regression. Specifically, an increase in the apoptotic ratio in adenomas was associated with a greater reduction in polyp number. Additionally, the ratio of apoptosis to cell proliferation in the superficial ( $AI_s/Ki-67_s$ ) compartment was predictive of clinical response. In normal colorectal

epithelia, the correlation between the  $AI_s$  and polyp regression was of borderline statistical significance. Of note, apoptotic events in normal mucosa occur with a reduced frequency relative to adenomas and our sample size was relatively small. Similar to our findings in adenomas, Keller et al. (33) found that sulindac treatment modulated the ratio of superficial to nonsuperficial apoptosis in normal rectal mucosa from FAP patients, which accompanied polyp regression. However, this same group found that the apoptotic ratio did not predict response to sulindac treatment nor adenoma development in genotype-positive, phenotype-negative FAP patients (34). While cell proliferation was not examined in those reports (33, 34), sulindac was shown to modulate cell proliferation in normal-appearing epithelia from FAP patients in one report (7) but not in others (35, 36). In our study, we clearly demonstrate that reduced cell proliferation in adenomas accompanies their regression. We emphasize that the correlations between biomarker modulation in adenomas and clinical response were highly statistically significant despite the relatively small sample size. While we were unable to establish any statistically significant correlations between biomarkers and study treatment arm, this does not mean that there is no such correlation. An association between celecoxib dose and  $Ki-67_s$  LI in adenomas was suggested when comparing the higher dose (400 mg twice daily) to the placebo group, where a large difference was suggested with respect to mean change in  $Ki-67_s$  from baseline to 6 months ( $-1.34$  for placebo and  $-16.28$  for 400 mg;  $P = 0.077$ ). The small study sample size limited the statistical power to detect significant associations among treatment arm and tissue biomarkers unless they were of extremely large magnitude. Taken together, our data suggest that celecoxib is modulating cell proliferation as well as the frequency and spatial distribution of apoptosis in colorectal mucosa from FAP patients. Alterations in cell kinetic parameters (i.e., hyperproliferation and attenuated apoptosis; refs. 20, 35) found in the colorectal mucosa of FAP patients may therefore be potentially reverted by celecoxib, suggesting that their modulation may be mechanistically related to the chemopreventive and antitumor efficacy of celecoxib in FAP.

Effective treatment of an established tumor requires that the tumor regress by a reduction in cell growth and/or an induction of apoptosis (18). A chemopreventive effect requires that an intervention interrupt or revert the cellular changes associated with tumorigenesis back to their normal physiological state. In normal colorectal mucosa, proliferating cells are restricted to the lower two-thirds of the crypts and apoptosis occurs predominantly in colonocytes at or near the luminal surface (17). These processes are dysregulated in FAP as indicated by an upward shift of the proliferative compartment and reduced superficial apoptosis in normal-appearing colorectal mucosa (19, 20). The distribution of proliferating and apoptotic cells have been shown to be topographically reversed in adenomatous polyps compared with normal colorectal mucosa. Specifically, colorectal adenomas have increased numbers of proliferating cells at or near the luminal surface and more frequent apoptotic cells at or near the crypt base (21, 22). Our results suggest that celecoxib may regress adenomas by reverting abnormal cellular kinetics toward the pattern found in

normal mucosa. Our findings are consistent with *in vitro* data for celecoxib where this drug and other NSAIDs inhibit cultured colon cancer cell growth, arrest cells in the G<sub>1</sub> phase of the cell cycle, and induce apoptosis (23-26). Furthermore, Mahmoud et al. (29) found that sulindac sulfide reverted the reduction in enterocyte apoptosis found in the intestinal mucosa of <sup>Apc</sup>Min mice, compared with normal littermates lacking the APC mutation, in association with its chemopreventive effect. These data suggest that NSAIDs may reverse the suppression of apoptosis resulting from a loss of APC function (37). In this regard, reexpression of APC in human colorectal cancer cells containing endogenous inactive APC alleles resulted in a substantial reduction in cell growth shown to be due to the induction of apoptosis (37). Other potential mechanisms by which NSAIDs induce apoptosis include nuclear factor-κB inhibition (38), ceramide production (39), induction of membrane receptor DR5 expression (40, 41), and mitochondrial cytochrome *c* release (42, 43).

We did not find evidence for suppression of PGE<sub>2</sub> levels in colorectal epithelia by celecoxib treatment although a high level of patient compliance was achieved. Our findings are consistent with a study in <sup>Apc</sup>Min mice where sulindac markedly reduced intestinal tumor number but did not alter the level of PGE<sub>2</sub> in intestinal tissues (44). Celecoxib is a selective inhibitor of the COX-2 enzyme and studies indicate that PGE<sub>2</sub> is regulated to a greater extent by the COX-1 isoform (10). We found previously that low-dose aspirin (81 mg per day) markedly suppressed rectal mucosal PGE<sub>2</sub> levels and to an equivalent extent as did higher doses (up to 650 mg per day; ref. 45). Furthermore, the nonselective COX inhibitor sulindac reduced PGE<sub>2</sub> levels in 11 FAP patients and such suppression correlated with adenoma regression (46). Marked interpatient heterogeneity in sulindac-induced PGE<sub>2</sub> suppression was observed. While methodologic issues may have impacted on our findings, it is highly plausible that the observed biomarker modulation and polyp reduction by celecoxib are independent of COX-2 inhibition. Considerable evidence indicates that NSAIDs exert their antitumor effects through both COX-dependent and COX-independent mechanisms (2). Interestingly, recent data by Gao et al. (47) demonstrate a second pathway for PG production that is independent of COX and would therefore not be inhibited by NSAIDs.

In summary, we found that cell proliferation and apoptosis are modulated in colorectal epithelia during a 6-month trial of continuous celecoxib versus placebo treatment in FAP patients. Such modulation was found to significantly correlate with the percentage reduction in colorectal polyp number. These findings suggest that the mechanism of celecoxib's chemopreventive and tumor-regressing effects are related to alterations in these cell kinetic parameters. Cell proliferation and apoptotic ratios in colorectal epithelia may therefore represent intermediate biomarkers for the efficacy of celecoxib in FAP patients and studies are warranted to further address this issue.

## References

- Gwyn K, Sinicrope FA. Chemoprevention of colorectal cancer. *Am J Gastroenterol* 2002;97:13-21.

- Sinicrope FA, Gill S. Role of COX-2 in colorectal carcinogenesis. *Cancer Metastasis Rev* 2004;23:63-75.
- Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. *Gastroenterology* 1992;101:635-9.
- Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effects of long-term sulindac therapy on colonic polyposis. *Ann Intern Med* 1991;115:952-4.
- Waddell WR, Loughry RW. Sulindac for polyposis of the colon. *J Surg Oncol* 1983;24:83-7.
- Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. *N Engl J Med* 1993;328:1313-6.
- Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. *Br J Surg* 1993;80:1618-9.
- Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. *Cell* 1991; 66:589-600.
- Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med* 2000;342:1946-52.
- Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? *Am J Physiol* 1996;270:G393-400.
- Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. *Gastroenterology* 1994;107:1183-8.
- Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. *Cancer Res* 1995;55:3785-9.
- Sinicrope FA, Lemoine M, Xi L, et al. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. *Gastroenterology* 1999;117:350-8.
- Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in *Apc delta716* knockout mice by inhibition of cyclooxygenase 2 (COX-2). *Cell* 1996;87:803-9.
- Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. *N Engl J Med* 2000;343:1520-8.
- Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? *Ann Intern Med* 2000; 132:134-43.
- Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. *J Cell Sci* 1994;107:3569-77.
- Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. *Cancer* 1994;73:2013-26.
- Mills SJ, Shepherd NA, Hall PA, Hastings A, Mathers JC, Gunn A. Proliferative compartment deregulation in the non-neoplastic colonic epithelium of familial adenomatous polyposis. *Gut* 1995;36:1-4.
- Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. *Cancer Res* 1995;55:1811-6.
- Sinicrope FA, Roddey G, McDonnell TJ, Shen Y, Cleary KR, Stephens LC. Increased apoptosis accompanies neoplastic development in the human colorectum. *Clin Cancer Res* 1996;2:1999-2006.
- Moss SF, Scholes JV, Holt PR. Abnormalities of epithelial apoptosis in multistep colorectal neoplasia demonstrated by terminal deoxynucleotide nick end labeling. *Dig Dis Sci* 1996;41:2238-47.
- Piazza GA, Rahm AL, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. *Cancer Res* 1995;55:3110-6.
- Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. *J Clin Invest* 1995;96:491-503.
- Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. *FEBS Lett* 2002;531:278-84.
- Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. *FASEB J* 2001;15:2742-4.
- Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. *Cancer Res* 1997;57: 1301-5.

28. Brown WA, Skinner SA, Malcontenti-Wilson C, Vogiagis D, O'Brien PE. Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. *Gut* 2001;48:660-6.
29. Mahmoud NN, Boolbol SK, Dannenberg AJ, et al. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. *Carcinogenesis* 1998;19:87-91.
30. Sinicrope F, Hart J, Hai-An H, Lemoine M, Michelassi F, Stephens LC. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. *Clin Cancer Res* 1999;5:1793-804.
31. Fizazi K, Martinez LA, Sikes CR, et al. The association of p21(WAF-1/CIP1) with progression to androgen-independent prostate cancer. *Clin Cancer Res* 2002;8:775-81.
32. Morrow JD, Scruggs J, Chen YQ, Zachert WE, Roberts LJ. Evidence that the E2-isoprostane, 15-E2t-isoprostane (8-iso-prostaglandin E<sub>2</sub>) is formed *in vivo*. *J Lipid Res* 1998;39:1589-93.
33. Keller JJ, Offerhaus GJ, Polak M, et al. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. *Gut* 1999;45:822-8.
34. Keller JJ, Offerhaus GJ, Hylind LM, Giardiello FM. Rectal epithelial apoptosis does not predict response to sulindac treatment or polyp development in presymptomatic familial adenomatous polyposis patients. *Cancer Epidemiol Biomarkers & Prev* 2002;11:670-1.
35. Pasricha PJ, Bedi A, O'Connor PM, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. *Gastroenterology* 1995;109:994-8.
36. Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. *Gastroenterology* 1994;106:362-6.
37. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. *Proc Natl Acad Sci U S A* 1996;93:7950-4.
38. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF- $\kappa$ B pathway. *J Biol Chem* 1999;274:27307-14.
39. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. *Proc Natl Acad Sci U S A* 1998;95:681-6.
40. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. *Cancer Res* 2002;1:4903-8.
41. Huang Y, He Q, Hillman MJ, Rong R, Sheikh MS. Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. *Cancer Res* 2001;61:6918-24.
42. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome-c-dependent apoptotic pathway in human colon cancer cells. *Cancer Res* 2002;62:6323-8.
43. He Q, Luo X, Huang Y, Sheikh MS. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. *Oncogene* 2002;21:6032-40.
44. Chiu CH, McEntee MF, Wheland J. Sulindac causes rapid regression of preexisting tumors in Min/mice independent of prostaglandin biosynthesis. *Cancer Res* 1997;57:4267-73.
45. Sample D, Wargovich M, Fischer SM, et al. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. *Cancer Epidemiol Biomarkers & Prev* 2002;11:275-9.
46. Giardiello FM, Spannhake EW, DuBois RN, et al. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. *Dig Dis Sci* 1998;43:311-6.
47. Gao L, Zachert WE, Hasford JJ, et al. Formation of prostaglandin E<sub>2</sub> and prostaglandin D<sub>2</sub> via the isoprostane pathway: a mechanism for the generation of bioactive prostaglandins independent of the cyclooxygenase. *J Biol Chem* 2003;278:28479-89.